WO2025196671 - IMIDAZOLINONE DERIVATIVE COMBINED WITH PD-1 OR PD-L1 INHIBITOR FOR USE IN THE TREATMENT OF TUMORS
National phase entry is expected:
Publication Number
WO/2025/196671
Publication Date
25.09.2025
International Application No.
PCT/IB2025/052895
International Filing Date
19.03.2025
Title **
[English]
IMIDAZOLINONE DERIVATIVE COMBINED WITH PD-1 OR PD-L1 INHIBITOR FOR USE IN THE TREATMENT OF TUMORS
[French]
DÉRIVÉ D'IMIDAZOLINONE COMBINÉ À UN INHIBITEUR DE PD-1 OU DE PD-L1 DESTINÉ À ÊTRE UTILISÉ DANS LE TRAITEMENT DE TUMEURS
Applicants **
KANGBAIDA (SICHUAN) BIOTECHNOLOGY CO., LTD.
Inventors
WEI, Yonggang
SUN, Yi
YE, Fei
Priority Data
202410320620.7
20.03.2024
CN
202410844582.5
27.06.2024
CN
202411367397.8
29.09.2024
CN
202411380132.1
30.09.2024
CN
202411380851.3
30.09.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3073 | |
| EPO | Filing, Examination, Granting | 19304 | |
| Japan | Filing, Examination, Granting | 2769 | |
| South Korea | Filing, Examination, Granting | 3459 | |
| USA | Filing, Examination, Granting | 7740 |
Total:
36,345
Contact Us
Abstract[English]
Provided is a use of a compound represented by general formula (I) in combination with PD-1 inhibitor or PD-L1 inhibitor in the preparation of an anti-cancer drug (I).[French]
L'invention concerne l'utilisation d'un composé représenté par la formule générale (I) en combinaison avec un inhibiteur de PD-1 ou un inhibiteur de PD-L1 dans la préparation d'un médicament anticancéreux (I).